If a drug blocks an enzyme's activity by reversibly binding to its active site, what type of inhibition is this?

If a drug blocks an enzyme's activity by reversibly binding to its active site, what type of inhibition is this?

• A. Lowering the enzyme's activation energy
• B. Feedback inhibition
• C. Competitive inhibition
• D. Noncompetitive inhibition

Answer: (C)

When a drug reversibly binds to the active site of an enzyme and inhibits its activity, this describes competitive inhibition. In competitive inhibition, the inhibitor resembles the substrate and competes with it for binding to the enzyme's active site. Since this binding is reversible, increasing the concentration of the substrate can overcome the inhibitory effect, which is a hallmark characteristic of competitive inhibitors. This type of inhibition does not lower the enzyme’s activation energy directly; rather, it interferes with substrate binding. Feedback inhibition, on the other hand, involves the end product of a metabolic pathway inhibiting an upstream process and is not limited to active site interactions. Noncompetitive inhibition involves binding to an enzyme at a site other than the active site, affecting enzyme activity regardless of substrate concentration, which further differentiates it from competitive inhibition. Thus, the specificity of reversible binding at the active site confirms competitive inhibition as the correct classification in this scenario.

When a drug reversibly binds to the active site of an enzyme and inhibits its activity, this describes competitive inhibition. In competitive inhibition, the inhibitor resembles the substrate and competes with it for binding to the enzyme's active site. Since this binding is reversible, increasing the concentration of the substrate can overcome the inhibitory effect, which is a hallmark characteristic of competitive inhibitors.

This type of inhibition does not lower the enzyme’s activation energy directly; rather, it interferes with substrate binding. Feedback inhibition, on the other hand, involves the end product of a metabolic pathway inhibiting an upstream process and is not limited to active site interactions. Noncompetitive inhibition involves binding to an enzyme at a site other than the active site, affecting enzyme activity regardless of substrate concentration, which further differentiates it from competitive inhibition. Thus, the specificity of reversible binding at the active site confirms competitive inhibition as the correct classification in this scenario.